Show simple item record

dc.contributor.authorDíez Villalba, Ander
dc.contributor.authorArrieta Aguirre, Inés ORCID
dc.contributor.authorCarrano, Giulia ORCID
dc.contributor.authorFernández de Larrinoa Santamaría, Iñigo
dc.contributor.authorMoragues Tosantos, María Dolores ORCID
dc.date.accessioned2024-08-08T10:17:14Z
dc.date.available2024-08-08T10:17:14Z
dc.date.issued2024-08
dc.identifier.citationVaccine 42(20) : (2024) // Article ID 125990es_ES
dc.identifier.issn1873-2518
dc.identifier.urihttp://hdl.handle.net/10810/69226
dc.description.abstractCandida albicans can cause superficial or systemic infections in humans, particularly in immunocompromised individuals. Vaccination strategies targeting specific antigens of C. albicans have shown promise in providing protection against invasive candidiasis. This study aimed to evaluate the immuno-protective capacity of a KLH conjugated complex peptide, 3P-KLH, containing epitopes from C. albicans antigens Als3, Hwp1, and Met6 in a murine model of hematogenously induced candidiasis. Mice immunized with 3P-KLH raised a specific antibody response, and protection against C. albicans infection was assessed. Immunized mice exhibited significantly lower fungal load in their kidneys compared to the control group. Moreover, 37.5 % of immunized mice survived 21 days after the infection, while all control animals died within the first nine days. These findings suggest that the 3P-KLH complex peptide, targeting C. albicans key antigens, elicits a protective immune response and reduces the severity of systemic Candida infection. In addition, the high binding affinity of the selected epitopes with MHC II alleles further supports the potential immunogenicity of this peptide in humans. This research provides insights into the development of novel immunotherapeutic approaches against invasive candidiasis.es_ES
dc.description.sponsorshipFunding for this work was provided by the University of the Basque Country UPV/EHU (GIU21/017) and the Basque Government (IT913-16). A. D. was supported by Fundación Jesus de Gangoiti Barrera. G. C. was supported by a Department of Education, Universities and Research of the Basque Country fellowship (PRE_2013_562).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectCandida vaccinees_ES
dc.subjectepitopeses_ES
dc.subjecthematogenously induced candidiasises_ES
dc.subjectAls3es_ES
dc.subjectMet6es_ES
dc.subjectHwp1es_ES
dc.titleA novel Candida albicans Als3, Hwp1 and Met6 derived complex peptide protects mice against hematogenously induced candidiasises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0264410X24005978es_ES
dc.identifier.doi10.1016/j.vaccine.2024.05.038
dc.departamentoesEnfermeríaes_ES
dc.departamentoesInmunología, microbiología y parasitologíaes_ES
dc.departamentoesQuímica aplicadaes_ES
dc.departamentoeuErizaintzaes_ES
dc.departamentoeuImmunologia, mikrobiologia eta parasitologiaes_ES
dc.departamentoeuKimika aplikatuaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license.
Except where otherwise noted, this item's license is described as © 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license.